The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence.
Alfred F Trappey
No relevant relationships to disclose
John S. Berry
No relevant relationships to disclose
Timothy J Vreeland
No relevant relationships to disclose
Diane F. Hale
No relevant relationships to disclose
Alan K. Sears
No relevant relationships to disclose
Sathibalan Ponniah
No relevant relationships to disclose
Sonia A. Perez
No relevant relationships to disclose
Guy T. Clifton
No relevant relationships to disclose
Michael Papamichail
No relevant relationships to disclose
Nathan M. Shumway
No relevant relationships to disclose
Elizabeth Ann Mittendorf
No relevant relationships to disclose
George Earl Peoples
Consultant or Advisory Role - Antigen Express